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Antibody responses are critical components of pro-
tective immune responses to many pathogens, but
parameters determining which proteins are targeted
remain unclear. Vaccination with individual MHC-II-
restricted vaccinia virus (VACV, smallpox vaccine)
epitopes revealed that CD4+ T cell help to B cells
was surprisingly nontransferable to other virion pro-
tein specificities. Many VACV CD4+ T cell responses
identified in an unbiased screen targeted antibody
virion protein targets, consistent with deterministic
linkage between specificities. We tested the deter-
ministic linkage model by efficiently predicting new
vacciniaMHC II epitopes (830% improvedefficiency).
Finally, we showed CD4+ T cell help was limiting for
neutralizing antibody development and protective
immunity in vivo. In contrast to the standard model,
these data indicate individual proteins are the unit
of B cell-T cell recognition for a large virus. Therefore,
MHC restriction is a key selective event for the antivi-
ral antibody response and is probably important for
vaccine development to large pathogens.
INTRODUCTION
Vaccines are one of the most cost-effective medical treatments
in modern civilization (Rappuoli et al., 2002). Vaccinia virus
(VACV) is the viral species used as the human smallpox vaccine.
The smallpox vaccine has been extraordinarily effective, having
brought about the worldwide eradication of smallpox disease
(Fenner et al., 1988). The smallpox vaccine is generally consid-
ered the gold standard of vaccines, and elucidating the immu-
nobiology underlying the protection provided by the smallpox
vaccine will continue to reveal vaccinology principles that can
be applied to future vaccine development against other infec-
tious scourges. However, identifying and analyzing the fine
specificities of the adaptive immune response to a large patho-gen—such as a poxvirus—is confounded by a number of factors,
not least of which is the starkmagnitudes of the potential peptide
targets of the T cell responses and the potential protein targets of
the antibody responses. As a result of these challenges, we pos-
sess only a piecemeal understanding of the fine specificities of T
cell and antibody responses to any large pathogen and therefore
have a thin understanding of the roles of each fine specificity in
protective immunity, thereby limiting our ability to rationally
design new vaccines against large and complex pathogens.
Although neutralizing antibodies are of primary importance in
the protection from smallpox provided by the smallpox vaccine
in animal models (Belyakov et al., 2003; Edghill-Smith et al.,
2005; Galmiche et al., 1999; Lustig et al., 2005) and humans
(Amanna et al., 2006; Demkowicz et al., 1992), CD4+ T cells
and CD8+ T cells are also of great value (Amanna et al., 2006;
Fang and Sigal, 2005; Tscharke et al., 2005; Xu et al., 2004).
Here, we have focused on understanding the relationship be-
tween antibody and CD4+ T cell responses to vaccinia virus in
mice, as part of a strategy to elucidate the value of individual
fine specificities, potential interrelationships between those
specificities, and the underlying immunobiological and virologi-
cal parameters that determine the emergence of protective
immune responses to a small subset of all possible specificities.
RESULTS
Exquisitely Selective Antigen-Specific T Cell Help
Infection of mice with VACV results is an acute infection charac-
terized by several days of high viral replication and viral loads
of >108 infectious virions; this is followed by a strong adaptive im-
mune response and viral clearance in 1–2 weeks (Amanna et al.,
2006; Harrington et al., 2002; Xu et al., 2004). IgG responses to
VACV are fully dependent on CD4+ T cell help, as shown by the
absence of VACV IgG in MHC-II-deficient mice (Figure 1A and
Xu et al. [2004]). We recently identified 14 VACVMHC II epitopes
after VACV infection of B6 mice (Moutaftsi et al., 2007). CD4+ T
cells of each specificity expressed CD40L after stimulation with
cognate peptide (Figure 1B), indicating their competence to pro-
vide B cell help. In an effort to boost the antiviral antibodyImmunity 28, 847–858, June 2008 ª2008 Elsevier Inc. 847
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CD4+ T Cell-B Cell Linkageresponses to VACV infection, we increased the available CD4+ T
cell helpby immunizingmicewith theVACV I121-35MHC II epitope
(one of the first epitopes identified from aVACV virion protein), in-
fecting the mice with VACV, and finally monitoring the subse-
quent antiviral antibody responses. Vaccinating with I121-35
MHC II epitope resulted in a strong 10-fold increase in the total
VACV antibody response, as measured by a standard VACV
ELISA (Figure 2A). Unexpectedly, virus neutralizing antibody
titers were unimproved in VACV-infected mice preimmunized
with I121-35 when compared to unprimed mice (Figure 2B). Al-
though I1 is a viral virioncoreprotein and thereforenot itself a neu-
tralizing antibody target, Il-specificCD4+Tcellswere expected to
provide intermolecular help to all B cells specific for VACV viral
particle proteins and thereby boost neutralizing antibody titers
(Janeway et al., 2005). Surprisingly, when serum samples were
probed for the detailed antigen specificities of the antibody re-
sponse with vaccinia protein microarrays, we found the increased
antibody response was exclusively against I1 and not other VACV
proteins (Figures 2C–2H). IgG specific for virion coreprotein I1was
increased 1930% (p < 0.0004) (Figure 2E). A10 is a second major
core protein present alongwith I1 in VACVvirions, andA10 is a tar-
get of the antiviral IgG response in infected B6 mice (see below).
Nevertheless the strength of the anti-A10 IgG response was unal-
tered in I1MHC II epitope vaccinatedmice (Figure 2F). The IgG re-
sponses to two vaccinia surface membrane protein virion compo-
nents, D8 and H3, also exhibited no improvement (Figures 2G and
2H).Selective increase inanti-I1 IgGwasstillobservedatamemory
timepoint (Figure2I). Thus, antigen-specificCD4+Tcells appeared
Figure 1. Vaccinia Virus CD4+ Helper T Cells
and Helper T Cell Dependent Antibodies
(A) Quantitative ELISA of anti-VACV IgG (mg/ml),
day 30 after infection in wild-type (WT) and MHC
II-deficient (H2-Ab/) mice. The graph shows
mean ± SEM.
(B) Splenocytes from day 10 VACVWR-infected
mice were incubated with CD11c+ dendritic cells
(DCs) pulsed with VACV peptides (L4, J4, etc.,
names corresponding to the VACV protein from
which each peptide epitope was derived). Cells
were incubated for 6 hr and then stained for intra-
cellular IFNgandCD40L.GatedCD4+CD62Llo lym-
phocytes are shown, and percentages quantified
are IFNg+ CD40L+ of CD4+ CD62Llo. DCs infected
with VACVWR (MOI = 5) for 2 hr prior to addition of
splenocyteswereused forquantificationof the total
anti-VACV CD4+ T cell response (bottom right,
‘‘VACV+ DCs’’). Background levels were deter-
minedwith uninfected DCs (‘‘neg’’). Low-frequency
A28-specific response was only detectable by
ELISPOT (not shown). Results are representative
of three (A) and four (B) independent experiments.
to provide help only to B cells of paired
protein specificity, not virion specificity.
Antibody Response Selectivity
Driven by Antigen-Specific CD4+
T Cells
To directly establish the role of antigen-
specific CD4+ T cells in the selective tar-
geting of individual viral virion proteins for antibody responses,
we performed CD4+ T cell adoptive-transfer experiments.
CD4+ T cells were purified from donor mice immunized with
I121-35 MHC II epitope, and cells were transferred into unimmu-
nized recipient mice. Recipient mice were infected with VACV
and examined for VACV antibody responses. Mice receiving
primed CD4+ T cells responded with a dramatic increase in
anti-I1 IgG (1210% enhancement, p < 0.0001) (Figures 3A–3C),
whereas the antibody responses to other viral virion protein
specificities remained unchanged (Figures 3A, 3B, 3D, and 3E),
starkly ignorant of the CD4+ T cells transferred from the VACV
I121-35-vaccinated mice.
This observation of paired targeting by the CD4 T cell and an-
tibody response indicates that CD4+ T cell help is preferentially
provided to B cells with the identical protein specificity, even
though the viral particle exists as a solid physical structure as-
sembled from greater than 75 distinct viral protein components
(Chung et al., 2006; Condit et al., 2006; Moss, 2001; Resch
et al., 2006) and this structure is expected to function as a unified
immunological target for B cells and B cell-T cell (B-T) interaction
(Janeway et al., 2005; Milich et al., 1987; Russell and Liew, 1979;
Scherle and Gerhard, 1986). Naked unwrapped viral nucleopro-
tein core particles are released from dying infected cells and
would be expected to function in the same manner.
To determine whether these I1 core protein results were gen-
eralizable, we tested the properties of several additional VACV
CD4+ T cell responses shown in Figure 1. We chose MHC II epi-
topes from H3 and D8 because these major virion surface848 Immunity 28, 847–858, June 2008 ª2008 Elsevier Inc.
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CD4+ T Cell-B Cell Linkagetransmembrane proteins are key IgG targets (Amanna et al.,
2006; Davies et al., 2005b) and are ostensibly recognized by B
cells as prominent components of the surface of whole virions.
In addition, we tested the vaccinia L4176-190 MHC II epitope, rep-
resenting a second major viral particle core component, to com-
Figure 2. Selective Protein-Specific CD4+
T Cell Help to B Cells after VACV Infection
Mice peptide vaccinated with VACV I121-35 MHC II
epitope were then infected with vaccinia virus. (A)
shows Vaccinia-specific IgG responses in VACV-
infected mice primed with adjuvant alone (‘‘mock
prime,’’ open circles), I1-primed mice subse-
quently infected with VACV (squares), I1-primed
only mice (‘‘X’’ symbol), and uninfected control
mice (‘‘I’’ symbol) were measured by ELISA. n =
4/group. Error bars represent ± SEM. As shown
in (B), virus neutralizing antibody titers (PRNT50)
were measured in I1-primed and unprimed mice
(p > > 0.05). I121-35 MHC II peptide-primed mice
(‘‘+,’’ n = 4) and mock-primed mice (‘‘,’’ adju-
vant-only prime; n = 4) were tested after VACV in-
fection. Shown ismean ± SEM. (C)–(I) show results
with sets of VACV proteins were synthesized and
printed in microarray format for generation of
VACV proteome arrays that could be probed
with serum samples (see Experimental Proce-
dures). VACV proteome microarrays were probed
with serum day 7 after VACV infection from mice
primed with I121-35 MHC II epitope or mock
primed. (C) and (D) show IgG responses of individ-
ual representative mice (C) primed with I121-35
MHC II epitope or (D) mock primed. Stars indicate
the anti-I1 signal. Error bars indicate range of rep-
licates. (E)–(H) show antibody responses to indi-
vidual vaccinia-virus protein determinants after
VACVWR infection in groups of I121-35 MHC II pep-
tide-primed mice (‘‘+,’’ n = 4) and mock-primed
mice (‘‘,’’ adjuvant-only prime. n = 4). Quantita-
tion of anti-I1 IgG ([E], p < 0.0004), anti-A10 IgG
([F], p >> 0.05), anti-D8 IgG ([G], p >> 0.05), and
anti-H3 IgG ([H], p >> 0.05) concentrations were
determined. Graphs show mean ± SEM (I) IgG re-
sponses in I1-primed and not primed mice at day
30 after VACV infection. Anti-I1 IgG (p < 0.02),
anti-A10 (p >> 0.05), and anti-D8 (p >> 0.05) re-
sponses were measured. *p < 0.05, **p < 0.01,
and ***p < 0.001. Data are representative of five
independent experiments.
pare with the responses to the I1 core
protein. Antiviral IgG responses were en-
hanced after VACV infection of mice
primed with any one of the three new
VACV MHC II epitopes (Figure 4A).
VACV proteome microarray serological
analysis again revealed a remarkable se-
lectivity of the antibody response in pep-
tide-vaccinated animals. In H3272-286
MHC-II-epitope-primed animals, anti-H3
IgG was increased dramatically (48-fold
increase, p < 0.0001) (Figure 4B). H3 is
a known target of neutralizing antibodies
(Davies et al., 2005b; Lin et al., 2000),
and virus neutralizing antibody titers were selectively increased
in mice with H3-specific CD4+ T cells (Figure 4C, p < 0.02).
Anti-A10 IgG concentrations were unaltered (Figure 4B), con-
firming and expanding the results first obtained for I1 (Figure 2).
Anti-H3 IgM concentrations were also selectively increasedImmunity 28, 847–858, June 2008 ª2008 Elsevier Inc. 849
Immunity
CD4+ T Cell-B Cell Linkage(Figures 4Dand4E). Particularly noteworthy, becauseH3 is a sur-
face virion protein, was the observation that IgG responses
against a second transmembrane surface virion protein, D8,
were unaltered in H3-primed animals (Figure 4F). In contrast,
anti-D8 IgG was increased substantially in D8238-252 CD4
+-epi-
tope-vaccinated mice (p < 0.03) (Figure 4G). The increased anti-
body response was again selective because anti-A10 IgG con-
centrations were unaltered (Figure 4G). The fourth target
tested, L4, confirmed and extended the results seen above for
I1, H3, and D8. Anti-L4 IgG concentrations were boosted in
mice vaccinated with L4176-190 MHC II peptide, but the remain-
der of the vaccinia antibody response was unaltered (Figure 4H).
Matched Immunodominant Antibody and CD4+ T Cell
Responses during Poxvirus Infection
The results above suggest that each antibody response need be
accompanied by a matched CD4+ T cell response to the same
Figure 3. CD4 T Cell-Dependent MHC II-Restricted Help for VACV
Antibody Response
Mice were immunized with a VACV MHC-II-binding peptide, I121-35. CD4
+ T
cells were purified from donor mice and transferred to unimmunized mice. Re-
cipient mice were then infected with VACV. (A) and (B) show quantitative anal-
ysis of IgG antibody responses to individual VACV proteins in representative
mice that received (A) I121-35 primed CD4
+ T cells or (B) did not receive primed
CD4+T cells. Stars indicate anti-I1 IgG. (C) shows anti-I1 IgG response in I121-35
MHC-II-peptide-primed CD4+ T cell recipient mice (‘‘+,’’ p < 0.0001, n = 3;
control mice ‘‘,’’ n = 4) was measured by microarray. Graphs show mean
± SEM. Anti-A10 (D) and anti-D8 (E) IgG responses measured as in (C). Data
are representative of two experiments.850 Immunity 28, 847–858, June 2008 ª2008 Elsevier Inc.protein, as if the virion were perceived as a collection of individ-
ual protein specificities, in contrast to the expectation that the vi-
rion behaves as a unified target with promiscuous CD4+ T cell
help. The standard assumption has been that no direct linkage
is required between B and CD4+ T cell responses to pathogens,
because the physical body of the pathogen (the virion or bacte-
rium) is expected to act as a unit, a unified target for B cell bind-
ing and subsequent processing and presentation to CD4+ T cells
(Janeway et al., 2005). This assumption can be succinctly sum-
marized as an ‘‘any-MHC-II-peptide-is-sufficient’’ model. That
is, a B cell binds cognate Ag on the virion and then internalizes
and processes the whole virion for Ag presentation, resulting in
the B cells presenting MHC II epitopes frommany different virion
proteins such that interaction with a CD4+ T cell specific for an
epitope from any of the virion proteins will result in a cognate in-
teraction and appropriate CD4+ T cell help to the B cell (termed
intermolecular help), as shown for influenza and HBV (Janeway
et al., 2005; Lake and Mitchison, 1976; Russell and Liew, 1979;
Scherle and Gerhard, 1986). However, our data demonstrate
an unexpectedly tight linkage between the protein specificity(ies)
of the CD4+ T cells and the protein specificity(ies) of the VACV
antibody response (intramolecular help), indicating that individ-
ual protein identities are the primary unit of immunological recog-
nition for a large pathogen. Indeed, recognition of the physical
vaccinia viral particle as a unit per se appears to be irrelevant be-
cause the recognition of I1 or H3 by CD4+ T cells is predomi-
nantly nontransferable to other virion components in the context
of B cell help: I1-specific CD4+ T cells did not provide help to B
cells of other virion protein specificities (Figures 2–4). This is of
great relevance because the vast majority of potential viral anti-
body targets are generally considered irrelevant for protective
immunity, and only virion surface proteins are relevant targets
for antibody-neutralization activity. This was demonstrated by
the failure to improve the neutralizing antibody response after
vaccination generating I1-specific CD4+ T cells (Figure 2B), in
contrast to the improved neutralizing antibody titers after vacci-
nation generating H3-specific CD4+ T cells (Figure 4C).
This led us to examine whether such CD4+ T cell-B cell linkage
is observed in the context of the natural VACV immune response.
Given the lack of predictive algorithms for identifying IAb binding
peptides (Rammensee et al., 1999; Sette et al., 1993), we identi-
fied the 14 MHC II VACV epitopes (Figure 1B) by screening an
unbiased, effectively random, set of 2146 15-mer peptides sam-
pling 31.5% of the VACV genome ORF sequences (see Experi-
mental Procedures). These epitopes represent 26%–33% of
the total anti-VACV CD4+ T cell response (Figure 1B, sum of all
epitopes compared to VACV-infected DC APCs), consistent
with the random distribution of the 2146 peptides screened
(see Experimental Procedures). Concurrent with our determina-
tion of the CD4+ T cell response specificities, we identified the
protein targets of the antiviral antibody response in VACV-in-
fected B6 mice by using a series of vaccinia proteome arrays
covering a total of 191 distinct genes (Figures 5A–5D and seeDa-
vies et al. [2005a] and Davies et al. [2005b]). The viral protein tar-
gets of the antibody response were determined by probing vac-
cinia proteome arrays with serum from >20 VACVWR infected
animals at day 30 after infection. Definitive IgG responses were
identified against 23 proteins, 17 of which were observed in
the majority of infected animals (Figures 5A–5E).
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CD4+ T Cell-B Cell LinkageFigure 4. Highly Selective CD4+ T Cell
Help to B Cells Specific for VACV Virion
Components
Antiviral antibody responses were measured in
mice immunized with vaccinia virus H3272-286,
D8238-252, or L4176-190 peptide MHC II epitopes
and then infected with VACV. (A) shows vaccinia-
specific IgG responses, measured by ELISA, in
VACV-infected mice primed with adjuvant alone
(‘‘mock primed,’’ open circles), H3-primed (closed
circles), D8-primed (closed squares), or L4-primed
(closed diamonds) mice subsequently infected
with VACV. Peptide primed only mice (‘‘X’’ symbol)
and untreated uninfected mice (+ symbol) served
as controls. n = 4/group. Error bars represent
+ SEM. In (B), the left panel shows anti-H3 IgG re-
sponse after VACV infection in H3272-286 MHC-II-
peptide-primed mice (‘‘+,’’ p < 0.0001, n = 11,
adjuvant only; ‘‘mock primed’’ mice, ‘‘,’’ n = 12;
composite data from three independent experi-
ments) are shown. The right panel shows anti-
A10 concentration (p >> 0.05). (C) shows virus-
neutralizing antibody titers (PRNT50) in H3-primed
and control mice. (D) shows vaccinia-specific IgM
responses, measured by ELISA in VACV-infected
(open circles), H3-primed (closed circles), I1-
primed (closed squares), D8-primed (closed trian-
gles), or L4-primed (closed diamonds) mice sub-
sequently infected with VACV. CFA-primed-only
mice (+ symbol) served as controls. n = 4/group.
Mean ± SEM is shown. (E) shows anti-H3 IgM
(left panel) and anti-A10 IgM responses (right
panel) in H3272-286-primedmice (p < 0.0019 and p >> 0.05). (F) shows anti-D8 IgG response in H3272-286-primedmice (p > > 0.05). (G) shows anti-D8 IgG response
in D8238-252 MHC-II-peptide-primedmice (left panel: primed, ‘‘+,’’ p < 0.04, n = 4; adjuvant-only ‘‘mock-primed’’ mice, ‘‘,’’ n = 4). The right panel shows anti-A10
IgG (p >> 0.05). (H) shows anti-L4 IgG response in L4176-190 MHC-II-peptide-primedmice (left panel: primed, ‘‘+,’’ n = 4; adjuvant-only ‘‘mock-primed’’ mice, ‘‘,’’
n = 4). The right panel shows anti-A10 IgG response (p >> 0.05). *p < 0.05, **p < 0.01, and ***p < 0.001. Data are representative of three to five independent
experiments.Extensive overlap was observed between the antigens recog-
nized by the CD4+ T cells and the antibodies. Six of the VACV-
protein antigens exhibited matched antibody and CD4+ T cell re-
sponses (Figure 5E), representing 46% of the known CD4+ T cell
targets (6 of 13) and 26% of the antibody targets (6 of 23). Given
that VACV contains greater than 200 genes, this concurrence
was striking. Statistical analysis confirmed that this linkage
was highly unlikely to occur by chance (p < 0.0009, Fisher’s
exact test). In contrast, no statistically significant linkage was
observed between the CD4+ T cell and CD8+ T cell targets, indi-
cating that these processes occur by distinct mechanisms
(Moutaftsi et al., 2007).
The six paired B cell-CD4+ T cell targets represented all three
major classes of viral proteins: virion surface proteins (H3, D8,
and A28), virion core proteins (I1 and L4), and nonstructural
proteins expressed within infected cells (D13). Also of note, the
CD4+ T cell target antigens not matched by an antibody re-
sponse were almost all (six of seven) viral transcription factors
and replication factors (A18 transcription factor, A20 DNA
polymerase cofactor, A24 RNA polymerase subunit, E1 polyA
polymerase, and J4 RNA polymerase subunit) (Figure 5E). We
speculate viral replication factors may be poor B cell antigens
because of low concentration or intracellular expression. This
is consistent with a model in which an antigen-specific B cell
response is dependent on a CD4 T cell response of matched
specificity but not vice versa.Prediction of Antiviral CD4+ T Cell Responses
on the Basis of Antibody Specificities
Prediction of CD4+ T cell response epitope specificities is diffi-
cult because of class II binding motif degeneracy and other con-
siderations (Rammensee et al., 1999; Sette et al., 1993). Further-
more, those difficulties are exacerbated by the sheer size of large
pathogens such as poxviruses. Given that our data show the
VACV virion antibody responses are restricted by protein
matched CD4+ T cell help (Figures 2–4), our model suggests
we should be able to predict additional VACV CD4+ T cell targets
by observing viral antibody target specificities. To test this
hypothesis, VACV IgG targets B5, A4, A27, B2, and A33 were
selected on the basis that CD4+ T cell responses had not been
detected to these targets in the first round of random screening
(Figure 1B and Experimental Procedures; see also Moutaftsi
et al. [2007]), but we nowpredicted that, for each antibody target,
the antibody response was predicated on amatched CD4+ T cell
response (Figure 5E). As negative controls, two virion proteins,
A9 and D3, that are not IgG targets were also selected. Overlap-
ping peptides representing the entirety of each protein were
screened with IFNg ELISPOT for detection of the presence of
epitope-specific CD4+ T cell responses in VACV-infected B6
mice. Responses were then confirmed by intracellular cytokine
staining of CD4+ T cells from VACV-infected mice (Figure 6A).
CD4+ T cell responses were identified against four of the five B
cell targets tested: B5, B2, A4, and A33 (Figure 6A), therebyImmunity 28, 847–858, June 2008 ª2008 Elsevier Inc. 851
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to 18. No CD4+ T cell responses were detected to control ORFs
A9 and D3. Strikingly, the response to B246-60 was the strongest
CD4+ T cell response of all 18 epitopes identified, and the B546-60
epitope was the third strongest response overall (Figure 6A,
compared with Figure 1B. We tested all peptides concurrently
to allow for direct quantitative comparisons, ranked in
Figure 6B). The four new epitopes accounted for 22% of the total
VACV-specific CD4+ T cells in infected mice, compared with
26% accounted for by the initially identified 14 epitopes. Taking
into consideration that 211 peptides were tested from the five
anti-VACV target proteins in the new selective screen versus
2146 random peptides in the original screen, we found that
Figure 5. Interrelationship between Anti-
VACV CD4+ T Cell and Antibody Responses
in Virus-Infected Mice
(A–C) Quantitative analysis of IgG antibody re-
sponses to individual VACV proteins in (A and B)
two representative VACV-infected B6 mice and
one (C) uninfected mouse, as measured by pro-
teomic microarray (RU, relative fluorescence
units). Stringent limit of detection is indicated by
dashed line. Panels are representative of >20
animals. Graphs show mean ± range.
(D) Representative immunofluorescence microar-
ray scan of VACV-protein microarray probed with
sera from an uninfected mouse versus a VACV-in-
fected mouse. Each VACV protein is presented as
duplicate spots.
(E) Tabulation of interrelationship between the an-
tiviral CD4+ T cell targets (columns) and antibody
targets (rows). Matched CD4+ T cell and antibody
specificities are indicated in red. Specificities are
ranked roughly in descending order on the basis
of strength of response (T cell targets, left to right;
antibody targets, top to bottom). A total of 17 IgG
targets were identified in the majority of infected
mice (shown), and variable IgG responses were
also seen to minor antigens F9, I3, A56, A17,
A13, and WR149 in some infected mice (not
shown, but included in the statistical analysis to
be conservative). B cell specificities subsequently
selected for prediction of CD4 T cell responses are
highlighted in yellow.
CD4+ T cell target identification via link-
age prediction based on serology repre-
sented an 830% increase in predictive
power over random screening of pep-
tides. This efficient strategy for CD4+ T
cell epitope identification has obvious
practical benefits for studying other
complex pathogens of interest.
Role in Protective Immunity In Vivo
Having predicted and identified a CD4+ T
cell response to B5, we then showed that
B5-specific CD4+ T cells provide selec-
tive help to B5-specific B cells. This is of
interest not only to confirm the prediction
but also because B5 is a important mem-
brane protein and neutralizing antibody target on the second
form of VACV viral particle, extracellular enveloped virion (EV),
which has a second outer-membrane layer, with distinct mem-
brane proteins, covering an inner membrane and virion core
that is identical to the much more abundant MV (mature virion)
viral particle form (which includes H3 and D8 as surface-mem-
brane proteins). Mice primed to generate a B5-specific CD4+ T
cell response and then infected with VACV develop an enhanced
B5 antibody response (Figure 7A, 4-fold increase, p < 0.04). Nor-
mal VACV antigen preparations are dominated by MV virion an-
tigens and contain only trace amounts of B5 (determined with B5
monoclonal antibody, data not shown), and therefore VACV MV
antigen ELISA was an efficient test for demonstrating that the B5852 Immunity 28, 847–858, June 2008 ª2008 Elsevier Inc.
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CD4+ T Cell-B Cell LinkageFigure 6. Utilization of Antibody Specific-
ities to Predict New Vaccinia Virus Protein
Targets of CD4 T Cell Responses
(A) IFNg and CD40L intracellular staining for VACV
B246-60-, B546-60-, A33116-130-, and A466-80-spe-
cific CD4+ T cells at day 10 after VACV infection.
Graphs are of gated CD4+ CD62Llo lymphocytes.
‘‘Neg’’ refers to no peptide control. As negative
controls, two virion proteins, A9 and D3, that are
not IgG targets were also selected. No CD4+ T
cell responses were detected to control ORFs A9
and D3 (data not shown).
(B) Tabulation of the full set of discovered interrela-
tionships between the antiviral CD4+ T cell targets
(columns) and antibody targets (rows). Eleven of
eighteen CD4+ T cell responses (highlighted in
red) are matched by IgG responses to the same
smallpox vaccine virus protein. Specificities are
ranked and marked as described above. Data are
representative of five independent experiments.CD4+ T cells only help B5-specific B cells because the overall
anti-VACV MV IgG response was not enhanced in mice with
pre-existing B5-specific CD4+ T cells (Figure 7A).
Knowing that B5 and H3 are both targets of protective neutral-
izing antibody responses (Benhnia et al., 2008; Chen et al., 2006;
Davies et al., 2005a; Lustig et al., 2005), we could test the biolog-
ical relevance of the T-B linkage in vivo in a lethal poxvirus chal-
lenge system. Mice were immunized with H3272-286 or B546-60
MHC II peptide after the standard immunizations done previ-
ously in this study, such that they possessed B5-specific CD4s
or H3-specific CD4s prior to intranasal challenge with 1 3 104
PFU VACVWR (1 LD50). Primed mice possessing B5 CD4s or
H3 CD4s were significantly protected from morbidity (weight
loss) after VACVWR infection compared to control adjuvant-
primed mice (Figure 7B, p < 0.007, p < 0.02), and primed mice
possessing I1 CD4s did not exhibit protection (p >> 0.05, data
not shown). This protection was dependent on the enhanced
neutralizing antibody response because the protectionmediated
by the B5- and H3-specific CD4s was completely lost in the ab-
sence of B cells, measured either by morbidity (Figure 7C) or
mortality (Figure 7D; B5, p < 0.02; H3; p < 0.0001) after VACVWR
intranasal challenge. Thus, matched CD4 T cell responses to
neutralizing antbody targets are necessary for effective neutral-
izing antibody responses and protective immunity to VACV.
DISCUSSION
Three distinct lines of evidence demonstrate the deterministic
linkage of B cell and CD4+ T cell specificities to this large virus:
(1) MHC II peptide vaccination results in highly selective CD4+
T cell help to matched B cells specific for the same viral virion
protein, (2) a strong overall correlation was found between
CD4+ T cell targets and antibody targets in vivo (p < 0.0009),
and (3) newMHC II epitopes recognized by antiviral CD4+ T cells
were efficiently predicted on the basis of this model (830%
increase in predictive power). In total, 11 of the 18 CD4+ T cellresponses we identified were matched by a paired antibody re-
sponse to the same viral protein, including all of the top five viral
protein IgG targets. Our results reveal an unexpectedly tight link-
age between the CD4+ T cell and antibody response specificities
for VACV—the first large viral pathogen examined in this manner.
Furthermore, we show that this is important for the generation of
neutralizing antibodies and in vivo protective immunity. Intermo-
lecular help has been a well-accepted viral immunology model
for 20 years, on the basis of data from influenza-virus studies
(Russell and Liew, 1979; Scherle andGerhard, 1986) and corrob-
orating evidence from hepatitis B virus (HBV) (Milich et al., 1987).
However, putative whole VACV viral particle uptake and antigen
presentation is not detectable, as measured by in vivo CD4+
T cell help.
We consider that there are two plausible reasons for why
whole VACV viral particle uptake and presentation is not ob-
served, and we consider that there are three feasible mecha-
nisms for how the virus-specific B cells are acquiring antigen
and T cell help. The first plausible reason for the failure of whole
VACV viral particle uptake and antigen presentation is a size re-
striction. There is a substantial size difference between the ex-
perimental pathogens being considered. VACV virions are large
(360 nm diameter) (Cyrklaff et al., 2005; Roos et al., 1996),
whereas flu virions are small (80 nm [Knipe and Howley, 2001]),
and HBV particles are smaller still (20–45nm [Knipe and Howley,
2001]). Antigen-specific uptake by B cells is via BCR-mediated
endocytosis, and endocytic vesicles are only 50–150 nm in diam-
eter (Goldstein et al., 1979; Lodish et al., 2003; West et al., 1994).
Thismay result in size exclusion at the level of cellular uptake and
would be a restriction generally applicable to large pathogens,
including large viruses, bacteria, and parasites. A second plausi-
ble reason for failure to observe whole VACV viral particle uptake
and presentation could be that viral particles are not ameaningful
source of antigen, either because of limiting numbers of virions
produced or limited accessibility to B cells. It may be that
VACV infection, although quite robust, does not reach the veryImmunity 28, 847–858, June 2008 ª2008 Elsevier Inc. 853
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other infections (For example, HBV infection results in systemic
serum virion levels in excess of 109 per ml, whereas VACV is nor-
mally undetectable [<102 per ml] in serum [Briody, 1959; Hollin-
ger and Liang, 2001].). This scenario would then be applicable to
a wide range of infections that result in midgrade physiological
concentrations of pathogen. Alternatively, the absolute number
of viral particles may not be the relevant parameter, but instead
accessibility of antigen to B cells is the key parameter. This issue
has been highlighted by several recent studies examining the im-
pact of lymph-node architecture on antigen acquisition by B
cells. Large multimolecular particles such as viruses (Hickman
Figure 7. Protective Immunity Induction In Vivo
(A) Antibody responses to B5 (left) and VACV MV (right) proteins after VACVWR
infection of B546-60 MHC-II-peptide-primed mice (‘‘+’’) and mock-primed mice
(‘‘,’’ adjuvant-only prime).
(B) Weight loss in B6 mice infected intranasally with VACVWR. Groups were
primed for generation of B5-specific CD4+ T cells (closed circles, n = 8) or
H3-specific CD4+ T cells (squares, n = 8) or primed with CFA adjuvant alone
(n = 8) prior to viral challenge.
(C) Weight loss in B cell-deficient mice (mMT) infected intranasally with
VACVWR. This experiment done concurrently with that of (B). n = 4 per group.
Graphs show mean ± SEM.
(D) Survival curves in B5 CD4+ T cell primed (left) and H3 CD4+ T cell-primed
(right) C57BL/6 (‘‘WT’’) and B cell-deficient mice after VACVWR challenge.
Data are representative of two independent experiments.854 Immunity 28, 847–858, June 2008 ª2008 Elsevier Inc.et al., 2008; Junt et al., 2007), bacteria (Carrasco and Batista,
2007), or antigens or comparable size (Carrasco and Batista,
2007; Phan et al., 2007) are excluded from diffusion into lymph
nodes. Viruses and other particulate antigens traffic through
lymph and are captured by macrophages that bridge the sub-
capsular sinus and the underlying B cell follicle. The particles
are then transferred to B cells that migrate deep into the follicle
to the T-B boundary (Carrasco and Batista, 2007; Junt et al.,
2007; Phan et al., 2007), where the B cells presumably initiate in-
teractions with CD4+ T cells. However, although VACV is ex-
cluded from freely diffusing through follicles (Hickman et al.,
2008; Junt et al., 2007), and VACV replication is highest in ovaries
(Briody, 1959; Xu et al., 2004), it is also known that VACV directly
infects lymph node and spleen cells (Briody, 1959; Hickman
et al., 2008) and has considerable access to cells in the lymph-
node medulla (Junt et al., 2007). Furthermore, DCs can retain in-
tact microbes (Balazs et al., 2002; Kwon et al., 2002; Macpher-
son and Uhr, 2004) and transfer antigens to B cells (Qi et al.,
2006; Wykes et al., 1998), suggesting multiple different routes
by which whole virions may encounter B cells.
Given those possible reasons why whole VACV virion uptake
and antigen presentation is not occurring at detectable levels,
there are three feasible mechanisms for how the B cell antigen
uptake and presentation is occurring during a VACV infection.
The first and simplest model is that VACV virions are not involved
(for reasons described above) and free individual viral proteins
are the physiological B cell antigens. Data are available that
support this model. Soluble proteins can be rapidly trafficked
through lymph and be acquired by lymph-node-resident B cells
(Pape et al., 2007). This has also been observed in the context of
a viral infection (VSV [Junt et al., 2007]). The appeal of this model
is only weakened by the consideration that monomeric soluble
antigens would fail to induce BCR crosslinking and signaling.
This lack of BCR signaling would fail to enrich for antibody re-
sponses to virion surface proteins presented in their appropriate
conformation. Because virion surface proteins are generally the
only physiologically relevant target antigens for neutralizing anti-
body responses, and virion surface protein-specific B cell re-
sponses are efficiently induced by the highly multimeric nature
of virions via extensive BCR crosslinking upon interaction with
a virus-specific B cell (Bachmann and Zinkernagel, 1997),
whole-virion binding by virus-specific B cells is the only opportu-
nity for the immune system to selectively enrich for B cell re-
sponses to neutralizing antibody targets. One could argue for
an intermediate level of macromolecular structure (subvirion
fragments or particles) such that sufficient copies of antigen
are available for BCR crosslinking (which may be occurring in
the context of VSV infection, as observed in Supplemental Fig-
ure 6 of Junt et al. [2007]), but this is an unlikely solution for large
viruses with complex virion protein mixtures because themacro-
molecular structures would have to be of a single-protein spe-
cies to fit the observation that CD4+ T cell help to VACV B cells
is highly protein specific. However, a second potential mecha-
nism would allow immunologic utilization of the information con-
tained in the multimeric nature of the virion: If B cells bind to
whole virions in vivo but are unable to internalize the large parti-
cle, the B cells may pinch off cognate antigen after forming an
immunological synapse with the target membrane (in this case,
the virion surface-membrane or infected cell). B cells are known
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et al., 2001) or planar membrane surfaces (Fleire et al., 2006) in
a BCR-mediated process, and the acquired antigen induces B
cell activation and is efficiently processed and presented to cog-
nate T cells (Batista et al., 2001; Fleire et al., 2006). Concentra-
tion of membrane-bound antigen by formation of an immunolog-
ical synapse and subsequent pinching of that antigen would
provide a mechanism both to enhance recognition of potential
neutralizing antibody targets via increased BCR mediated stim-
ulation and a mechanism for selective CD4+ T cell help. A third
potential mechanism for selective B-T interactions would be
preferential protection of cognate antigen by the BCR during
transport to intracellular antigen-processing compartments
(Watts, 1997). Further studies are required to discriminate be-
tween these mechanisms. Initial attempts to elucidate molecular
mechanismwere inconclusive because of the low frequencies of
antigen-specific B cells in vivo (data not shown), and therefore
BCR transgenics will be required to address this issue. Panels
of VACV hybridomas have now been generated and character-
ized (unpublished data), and BCR cloning and transgenic pro-
duction is underway. It will also be important to test the predic-
tion of B-T linkage for additional large pathogens and the
general power of serological analysis to greatly enhance predic-
tion and identification of novel CD4+ T cell epitopes for other
large pathogens of interest. It is intriguing to speculate that
these findings may also relate to the mechanisms underlying
B-T linkage to surface membrane proteins in cancer immunity
and autoimmunity (e.g., myasthenia gravis), for which the anti-
gen is present is the context of a whole cell.
The data presented herein demonstrate that the cellular mech-
anism driving the linkage of CD4+ T cell and antibody specific-
ities is a B cell requirement for intramolecular protein-specific
CD4+ T cell help. As such, MHC restriction at the protein level
is a key event for humoral immune responses to VACV because
individual protein identities are the primary unit of immunological
recognition. This is a powerful principle; we have shown that it
impacts protective immunity and can also be used to predict
the presence of novel pathogen-specific CD4+ T cell responses.
These findings from the smallpox vaccine virus are relevant for
understanding the nature of B cell antigen presentation to
CD4+ T cells and nonself recognition, the prediction of MHC II
epitopes, and vaccine development against complex patho-
gens. Because the smallpox vaccine is the only vaccine to result
in eradication of a disease from the human population, immuno-
logical results with this virus must be taken quite seriously.
EXPERIMENTAL PROCEDURES
Mouse Procedures and Viral Infections
C57BL/6J (B6), MHC class II/ (C57BL/6J Iab-Ea/), and B cell-deficient
(C57BL/6J mMT) mice were purchased from the Jackson Laboratory and
bred in house. VACVWR (Western Reserve strain) stocks were grown on
HeLa cells, infecting at a multiplicity of infection of 0.5 (MOI = 0.5). Cells
were harvested at 60 hr, and virus was isolated by rapid freeze-thawing the
cell pellet 33 in a volume of 2.3 ml RPMI + 1% FCS per T175 flask. Cell debris
was removed by centrifugation. Clarified supernatant was frozen at –80C as
virus stock (Davies et al., 2005b). Stocks were titered on VeroE6 cells. For all
experiments except Figures 6D–6F, mice were infected with VACVWR by bilat-
eral intraperitoneal (i.p.) injections of 2 3 105 or 2 3 106 total PFU total with
standard VACVWR stocks. Replicates of experiments in Figures 1, 2, 4, and 5
were also performed with purified VACVWR for infections; no differences inthe results were observed. Purified VACVWR stocks were made by centrifuging
standard VACVWR stock through a 36% sucrose cushion in PBS plus 5 mM
MgCl2 and resuspension of the virion pellet in RPMI + 1%FCS. For peptide im-
munizations, 30 mg peptide (or PBS control) was emulsified in CFA. Subcuta-
neous injections were done dorsal to the base of the tail; subcutaneous injec-
tions for some repeat experiments were done between the scapula. VACVWR
i.p. infections were done 11–13 days after peptide priming. For adoptive trans-
fers, untouched SMtg+ CD4 T cells were magnetically purified from spleen and
lymph-node preparations (MACS Miltenyi). A total of 50 3 106 CD4+ T cells
were transferred per mouse, resulting in approximately one-half mouse equiv-
alent of donor CD4+ T cells after take (e.g., 53 106 donor CD4 T cells/spleen).
For viral challenge experiments (Figures 6D–6F), 8-week-old female mice were
infected intranasally with 1 3 104 PFU VACVWR. Virus was placed in a volume
of 10 ml on the nares of lightly sedated mice and subsequently inhaled by the
mice. Mice were weighed daily to track disease progression. Dose-titration
experiments established 1 3 104 PFU VACVWR to be 1 LD50 in 8-week-old
female C57BL/6 mice (unpublished data). All animal experiments were con-
ducted in accordance with approved animal protocols.
ELISA
VACV ELISAs were done as described (Davies et al., 2005b), with the addi-
tional use in Figure 1 of standard curves with mouse IgG (Southern Biotech)
in anti-mouse Ig (goat anti-mouse IgM + IgG + IgA, Caltag)-coated wells. B5
ELISA used recombinant B5.
Protein Arrays and Analysis
We used 16-pad nitrocellulose FAST slides (Whatman) for protein microarray
printing. Proteins were printed at Scripps (TSRI) with a custom arrayer with
100 mm pins built by Robotic Labware Design (RLD). Humidity was maintained
at 40%–60% during printing. Microarray slides were subsequently dried
and stored in a desiccator at 80C. Vaccinia genes were cloned into pXi
(pNHisCHA derived [Davies et al., 2005b]) and sequenced prior to protein syn-
thesis with the Roche RTS E. coli in vitro-coupled transcription and translation
expression system. RTS reactions without plasmidwere used as negative con-
trols. Expression was confirmed by dot blotting, immunoblotting, ormicroarray
probing for His tags. Whole-virus antigen was printed with 10-fold concen-
trated, PBS buffer-exchanged, psoralen inactivated (Davies et al., 2005b)
standard VACVWR stock. Uninfected HeLa cell lysate processed identically
served as negative control (Crotty et al., 2003). Purified His-taggedH3L protein
(Davies et al., 2005b) was printed at 100 mg/ml. E. coli produced L1, F9, A21,
and A28 were purified and refolded under oxidizing conditions for generation
of natively folded protein with appropriate disulfide-bond formation (Su et al.,
2005). Secreted B5Rwas produced with a baculovirus expression vector in S2
insect cells and subsequently purified with an N-terminal His tag. All antigens
were resuspended in 0.02% Tween-20 prior to printing.
Mouse serum samples were initially screenedwith a large protein microarray
covering 185 VACV proteins (Davies et al., 2005b). Because only a minority of
VACV antigens elicit antibody responses in mice, humans, hyperimmune rab-
bits, or primates (Davies et al. [2005a], Davies et al. [2007], and D.D., S.C., P.F.,
unpublished data), the majority of experiments done in this study were done
with a compact microarray (Figure 5) consisting of 55 proteins identified as
an antibody target in any species, as well as all known virion surface proteins
(as of early 2005). This strategy allowed for an 8-fold increase in the numbers of
replicate experiments (16 pad microarray slide versus two pad microarray
slide). In addition, after the identification of VACV CD4 T cell targets (Figure 1),
we retested CD4 T cell target proteins without known IgG responses (J4, F15,
A20, E1, E9, A24, and A18) in a new set of microarrays to determine whether
any IgG targets had been missed, and no new IgG targets were detected. In
total, using several generations of microarrays, we tested 191 VACV proteins
for IgG responses, out of 218 total annotated VACVWR genes.
We used proteome microarrays to detect antibodies by techniques compa-
rable to a fluorescence ELISA on a microscale. After blocking arrays (Protein
Array Blocking Solution, Whatman), microarrays were probed with 1:50mouse
serum diluted in array-blocking solution preadsorbed for 30minwith 10% clar-
ified E. coli lysate. (Clarified E. coli lysate was prepared with 100 mg/ml DH5a
in PBS, sonicated, and centrifuged at 6000 g. Lysate was then stored
at 80C.) After 2 hr of incubation, extensive washing was done with PBS +
0.05% Tween-20, and secondary antibody (Cy3 labeled goat anti-mouseImmunity 28, 847–858, June 2008 ª2008 Elsevier Inc. 855
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at 1:50 in array-blocking solution was added for 1 hr. Cy5-labeled goat
anti-mouse IgM Fc-specific F(ab)2 immunoglobulin was also used in some ex-
periments. Arrays were then washed extensively with PBS + 0.05% Tween-20
and PBS alone and then spun dry. Arrays were scanned on an Axon 400B
GenePix (Molecular Dynamics), and data were acquired with GenePix Pro
5.1. Total 532 nm fluorescence intensity (TFI532) of each spot was the signal
strength. Background signal was subtracted out with relevant matched control
samples (e.g., RTS translation reaction without plasmid), and background-
subtracted signal was converted to the final IgG relative units (RU) via 106
transformation. Data are plotted as the average of duplicate protein prints
(spots), with the full range shown as the error bar (e.g., Figures 5A–5C). Strin-
gent signal thresholds were established as 1 RU above background, and this
unit was greater than 103 the background observed in uninfected animals for
individual protein antigens (Figure 5). With these experimental conditions, IgG
signals detected by protein microarray are linear and correlate tightly with sig-
nals observed by conventional endpoint dilution ELISA.
Neutralization Assays
VeroE6 cells were seeded into 24-well Costar plates (Corning) and used within
24 hr of reaching 90% confluency. Mouse serum samples were collected by
retro-orbital bleed fromB6mice at various time points after infection. All serum
samples were heat-inactivated prior to use (56C, 30 min). Diluted sera were
incubated in an equal volume of sonicated sucrose gradient purified VACVWR
(104 PFU/ml) overnight at 37C, 5% CO2 (Newman et al., 2003). Negative con-
trol sera from untreated mice were also done at the same conditions. The me-
dium from 24-well plate was aspirated, and 100 ml of virus/serum mixture was
added to each well and left to adsorb for 60 min at 37C with periodic swirling.
The infected VeroE6 cells were rinsed with warm PBS. One ml of complete D-
10 medium (DMEM + 15% FBS + pen/strep + L-glut) was then added, and the
plates were incubated for 40–50 hr. Medium was then aspirated, cells were
fixed and stained in one step with 0.1% crystal violet in 20% ethanol, and pla-
ques were quantified over white-light transillumination. Fifty percent of plaque
reduction neutralization titer (PRNT50) was defined as the furthest dilution of
each sample to neutralize >50% the virus according to the formula: [(PN
VACV – PN sample)/PN VACV], where ‘‘PN VACV’’ is the average number of
plaques in wells infected with VACVWR alone and ‘‘PN sample’’ is the average
number of plaques for a serum sample at a given dilution.
CD4+ T Cell Assays and MHC II Epitope Screening
Initial VACV epitope screening by IFNg ELISPOT was described (Moutaftsi
et al., 2007). The 2146 15-mer peptides represented 31.5% of the VACV ge-
nome-coding sequence. These peptides were synthesized for various pur-
poses, without consideration of antibody targets or other potential biases,
such that the peptide screening library randomly queried sequences through-
out the VACV amino acid sequence space. The peptides represented 199 of
the 218 annotated VACV genes (18 of 19 missed ORFs are less than 80 amino
acids in length). In the 2146 peptides (32,190 amino acids), 30% of total struc-
tural protein sequence and 31% of total nonstructural protein sequence were
represented. The percentage of the anti-VACV CD4+ T cell response identified
with these peptides (26%–33%, Figure 1B) was consistent with the random
distribution and overall VACV sequence coverage of the peptides (31.5%). In
addition, we could retroactively examine the peptide-library contents for
bias in coverage of known antibody targets, and no bias is present (30.7%
amino acid coverage of antibody targets versus 30.4% coverage of other), in-
dependently confirming the unbiased nature of the peptide library used.
The overlapping peptides used in Figure 6 were synthesized as 15-mers
overlapping by 5 amino acids on each end. We calculated increased epitope
identification predictive power via utilization of antibody targets (Figure 6) by
summing the CD4+ T cell responses to each epitope of interest (Figure 1B
and Figure 6A, experiments done at the same time) and then dividing by the
total anti-VACV CD4 T cell response (Figure 1B). This was then divided by
the number of peptides screened in each group.
Intracellular cytokine staining of splenocytes from VACVWR-infected mice
(day 7 or 10 after infection) was done by incubation of splenocytes with pep-
tide-pulsed CD11c+ DC for 1 hr prior to addition of brefeldin A. After 5 hr, cells
were surface stained for CD62L and CD4 surface molecules; this was followed
by intracellular staining for IFNg and CD40L. IFNg-producing and/or CD40L856 Immunity 28, 847–858, June 2008 ª2008 Elsevier Inc.expressing cells were determined by gating lymphocytes on FSC/SSC and
then gating on CD62L low/CD4+ T cells. CD11c+ DCs infected with VACVWR
(MOI = 5) for 2 hr prior to addition of splenocytes were used for identification
of the total anti-VACV CD4+ T cell response. We generated DCs by subcuta-
neous implantation of Flt3L-producing B16 cells and then by harvesting
CD11c+ DCs from spleen at day 12 after implantation, with CD11c paramag-
netic beads (MACS Miltenyi). Background level was established with CD4+
T cell values in the presence of uninfected CD11c+ DCs. All antibodies were
purchased from eBiosciences or BD PharMingen.
Statistics
Tests were performed with Prism 4.0 (GraphPad) or VassarStats (Fisher’s ex-
act test). Statistics were done with two-tailed, unpaired Student’s t test with
95% confidence bounds unless otherwise indicated. Bar graph error bars
are ± 1 SEM, except for raw microarray data, which show full range (e.g., Fig-
ures 5A–5C). Arithmetic means were used for all analyses. CD4+ T cell-anti-
body linkage (Figure 5E) was analyzed with Fisher’s exact test with the null hy-
pothesis being no increased frequency of antibody targets among the CD4+ T
cell target proteins. Six CD4+ T cell target proteins were IgG targets; seven of
themwere not. Twenty-three of 191 VACV proteins screenedwere IgG targets.
We did statistical analysis of mouse weight loss after intranasal infection with
VACVWR (Figures 6D and 6E) by tabulating the weight nadir (or 70% for dead
mice, which was the maximum weight loss before euthanization) for each
mouse and then comparing each experimental group by standard two-tailed,
unpaired Student’s t test with 95% confidence bounds. Survival-curve signif-
icance was calculated with Kaplan-Meier statistical analysis.
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